Ann: BIT225 HIV/HCV TRIAL PATIENTS VIRUS FREE AT , page-2

re: Ann: BIT225 HIV/HCV TRIAL PATIENTS VIRUS ... So who is pulling the wool?

From the HCV Central website:

"Genotype 1 is the most common type of Hepatitis C genotype in the United States and the most difficult to treat. For physicians, knowing the genotype of Hepatitis C is helpful in making a therapeutic recommendation. Individuals with genotypes 2 and 3 are almost three times more likely than individuals with genotype 1 to respond to therapy with alpha interferon or the combination of alpha interferon and ribavirin."

This is the common theme on the many sites I have encountered over the years.

I wish they would make a deal with a company to test this great drug in combination with the new DAAs on the block. Persisting with the soon to be outdated interferon and Ribavirin seems illogical to me. I would bet this drug will work with aplomb with newer drugs.

Great news for them of course but one should remember that whilst on the treatment the virus rarely makes a comeback so this news is really not news IMO. Having said that I doubt the virus will make a comeback after the treatment is finished.

Sold out.